Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial
2007-01-01 Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Passalacqua, R
Safety of targeted therapies (TTs) in metastatic renal cell carcinoma (mRCC) patients in haemodialysis (HD)
2013-01-01 Masini, C; Porta, C; Milella, M; Procopio, G; Di, Lorenzo G; Santoni, M; Buti, S; Iacovelli, R; Invernizzi, R; Moscetti, L; Aste, Mg; Pagano, M; Grosso, F; Manenti, Al; Ortega, C; Cosmai, L; Nicodemo, M; Donati, D; Del Giovane, C; Sabbatini, R
TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents
2017-01-01 Grassi, P; Verzoni, E; Bearz, A; Bracarda, S; Bregni, M; Buti, S; Cinieri, S; De Giorgi, U; Fornarini, G; Galli, L; Milella, M; Morelli, F; Nole, F; Passalacqua, R; Sabbatini, R; Santini, D; Salvioni, R; Cappelletti, V; Ratta, R; Procopio, G
Long-term results and health-related quality of life (QoL) after a bladder preservation program using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Effects of p53 and others predictive markers
2009-01-01 Brighenti, M; Passalacqua, R; Naldi, N; Buti, S; Lazzarelli, S; Potenzoni, D; Potenzoni, M; Benecchi, L; Fumagalli, M; Losardo, ; Monica, B; Caminiti, C
Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial
2012-01-01 Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; Pappagallo, Gl; Galligioni, E
Correlazione TC-PET nel follow-up di GIST metastatici trattati con terapia antitirosinchinasica (Imatinib)
2008-01-01 Mazza, G; Archiati, E; Voltini, G; Olivetti, L; Buti, S; Passalacqua, R
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWN): A preliminary report
2014-01-01 Bracarda, S; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Harnzaj, A; Altavilla, A; De Angelis, V
Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial
2007-01-01 Buti, S; Brighenti, M; Dalla Chiesa, M; Simonelli, C; Passalacqua, R
LOH as "the missing instability" potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer
2016-01-01 Bersanelli, M; Gnetti, L; Azzoni, C; Bottarelli, L; Gasparro, D; Leonardi, F; Silini, Em; Buti, S
Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)
2017-01-01 De Giorgi, U; Procopio, G; Guida, A; Bearz, A; Buti, S; Basso, U; Mitterer, M; Ortega, C; Bidoli, P; Ferrau, F; Crino, L; Frassoldati, A; Marchetti, P; Mini, E; Scoppola, A; Verusio, C; Fornarini, G; Carteni, G; Caserta, C; Sternberg, Cn
TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC)-Liquid biopsy for biomarkers discovery
2016-01-01 Verzoni, E; Bearz, A; Bracarda, S; Bregni, M; Buti, S; Cinieri, S; De Giorgi, U; Fornarini, G; Galli, L; Milella, M; Morelli, F; Nole, F; Passalacqua, R; Sabbatini, R; Santini, D; Salvioni, R; Cappelletti, V; Grassi, P; De Braud, Fg; Procopio, G
Overexpression of p53 protein predicts complete response to chemoradiation therapy in T2-T4 bladder cancer: Ten years follow up
2007-01-01 Brighenti, M; Naldi, N; Caminiti, C; Potenzoni, D; Fumagalli, M; Crafa, P; Buti, S; Passalacqua, R
Outcome of patients with progressing oligometastatic renal cell carcinoma treated with locoregional therapy: a multicenter retrospective analysis
2017-01-01 De Lisi, D; Maruzzo, M; Galli, L; Biasco, E; Farnesi, A; Procopio, G; Ratta, R; Buti, S; Sternberg, Cn; Cerbone, L; Di Lorenzo, G; Pantano, F; Sterpi, M; De Giorgi, U; Berardi, R; Torinai, M; Camerini, A; Massari, F; Tonini, G; Santini, D
Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): results and evaluation of circulating T-regulatory cells (Treg) and other cytokines. A GOIRC study
2010-01-01 Passalacqua, R; Buti, S; Simonelli, C; Rivoltini, L; Castelli, C; Camisaschi, C; Lo Re, G; Lleshi, A; Donnini, M; Lazzarelli, S
Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?
2014-01-01 Santoni, M; Conti, A; Porta, C; Cerbone, L; Procoplo, G; Basso, U; De Giorgi, U; Rizzo, M; Ortega, C; Masser, F; Iacovelli, R; Masini, C; Milelia, M; di Lorenzo, G; Pagano, M; Buti, S; Falconi, M; Burattini, L; Santini, D; Cascinu, S
Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study
2006-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Lazzarelli, S; Donati, G
CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
2017-01-01 Masini, C; Vitale, Mg; Maruzzo, M; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Guida, A; Atzori, F; Mucciarini, C; Scagliarini, S; Vignani, F; Prati, G; Cosmai, L; Berselli, A; Pinto, C
Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial)
2012-01-01 Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; De Vivo, R; Pappagallo, Gl; Galligioni, E
Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-alpha (IFN-alpha), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial
2007-01-01 Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Mazza, G; Passalacqua, R
CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
2017-01-01 Masini, C; Vitale, Mg; Maruzzo, M; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Guida, A; Atzori, F; Mucciarini, C; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Berselli, A; Pinto, C
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial | 1-gen-2007 | Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Passalacqua, R | |
| Safety of targeted therapies (TTs) in metastatic renal cell carcinoma (mRCC) patients in haemodialysis (HD) | 1-gen-2013 | Masini, C; Porta, C; Milella, M; Procopio, G; Di, Lorenzo G; Santoni, M; Buti, S; Iacovelli, R; Invernizzi, R; Moscetti, L; Aste, Mg; Pagano, M; Grosso, F; Manenti, Al; Ortega, C; Cosmai, L; Nicodemo, M; Donati, D; Del Giovane, C; Sabbatini, R | |
| TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents | 1-gen-2017 | Grassi, P; Verzoni, E; Bearz, A; Bracarda, S; Bregni, M; Buti, S; Cinieri, S; De Giorgi, U; Fornarini, G; Galli, L; Milella, M; Morelli, F; Nole, F; Passalacqua, R; Sabbatini, R; Santini, D; Salvioni, R; Cappelletti, V; Ratta, R; Procopio, G | |
| Long-term results and health-related quality of life (QoL) after a bladder preservation program using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Effects of p53 and others predictive markers | 1-gen-2009 | Brighenti, M; Passalacqua, R; Naldi, N; Buti, S; Lazzarelli, S; Potenzoni, D; Potenzoni, M; Benecchi, L; Fumagalli, M; Losardo, ; Monica, B; Caminiti, C | |
| Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial | 1-gen-2012 | Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; Pappagallo, Gl; Galligioni, E | |
| Correlazione TC-PET nel follow-up di GIST metastatici trattati con terapia antitirosinchinasica (Imatinib) | 1-gen-2008 | Mazza, G; Archiati, E; Voltini, G; Olivetti, L; Buti, S; Passalacqua, R | |
| Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWN): A preliminary report | 1-gen-2014 | Bracarda, S; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Harnzaj, A; Altavilla, A; De Angelis, V | |
| Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial | 1-gen-2007 | Buti, S; Brighenti, M; Dalla Chiesa, M; Simonelli, C; Passalacqua, R | |
| LOH as "the missing instability" potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer | 1-gen-2016 | Bersanelli, M; Gnetti, L; Azzoni, C; Bottarelli, L; Gasparro, D; Leonardi, F; Silini, Em; Buti, S | |
| Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP) | 1-gen-2017 | De Giorgi, U; Procopio, G; Guida, A; Bearz, A; Buti, S; Basso, U; Mitterer, M; Ortega, C; Bidoli, P; Ferrau, F; Crino, L; Frassoldati, A; Marchetti, P; Mini, E; Scoppola, A; Verusio, C; Fornarini, G; Carteni, G; Caserta, C; Sternberg, Cn | |
| TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC)-Liquid biopsy for biomarkers discovery | 1-gen-2016 | Verzoni, E; Bearz, A; Bracarda, S; Bregni, M; Buti, S; Cinieri, S; De Giorgi, U; Fornarini, G; Galli, L; Milella, M; Morelli, F; Nole, F; Passalacqua, R; Sabbatini, R; Santini, D; Salvioni, R; Cappelletti, V; Grassi, P; De Braud, Fg; Procopio, G | |
| Overexpression of p53 protein predicts complete response to chemoradiation therapy in T2-T4 bladder cancer: Ten years follow up | 1-gen-2007 | Brighenti, M; Naldi, N; Caminiti, C; Potenzoni, D; Fumagalli, M; Crafa, P; Buti, S; Passalacqua, R | |
| Outcome of patients with progressing oligometastatic renal cell carcinoma treated with locoregional therapy: a multicenter retrospective analysis | 1-gen-2017 | De Lisi, D; Maruzzo, M; Galli, L; Biasco, E; Farnesi, A; Procopio, G; Ratta, R; Buti, S; Sternberg, Cn; Cerbone, L; Di Lorenzo, G; Pantano, F; Sterpi, M; De Giorgi, U; Berardi, R; Torinai, M; Camerini, A; Massari, F; Tonini, G; Santini, D | |
| Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): results and evaluation of circulating T-regulatory cells (Treg) and other cytokines. A GOIRC study | 1-gen-2010 | Passalacqua, R; Buti, S; Simonelli, C; Rivoltini, L; Castelli, C; Camisaschi, C; Lo Re, G; Lleshi, A; Donnini, M; Lazzarelli, S | |
| Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery? | 1-gen-2014 | Santoni, M; Conti, A; Porta, C; Cerbone, L; Procoplo, G; Basso, U; De Giorgi, U; Rizzo, M; Ortega, C; Masser, F; Iacovelli, R; Masini, C; Milelia, M; di Lorenzo, G; Pagano, M; Buti, S; Falconi, M; Burattini, L; Santini, D; Cascinu, S | |
| Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study | 1-gen-2006 | Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Lazzarelli, S; Donati, G | |
| CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure | 1-gen-2017 | Masini, C; Vitale, Mg; Maruzzo, M; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Guida, A; Atzori, F; Mucciarini, C; Scagliarini, S; Vignani, F; Prati, G; Cosmai, L; Berselli, A; Pinto, C | |
| Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial) | 1-gen-2012 | Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; De Vivo, R; Pappagallo, Gl; Galligioni, E | |
| Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-alpha (IFN-alpha), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial | 1-gen-2007 | Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Mazza, G; Passalacqua, R | |
| CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure | 1-gen-2017 | Masini, C; Vitale, Mg; Maruzzo, M; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Guida, A; Atzori, F; Mucciarini, C; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Berselli, A; Pinto, C |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Articolo su rivista1767
Data di pubblicazione
- 2020 - 2025192
- 2010 - 2019832
- 2000 - 2009517
- 1990 - 1999174
- 1980 - 198951
- 1979 - 19791
Editore
- ELSEVIER25
- SAGE PUBLICATIONS LTD17
- DIKE GIURIDICA15
- Elsevier13
- ASCO pubs11
- ELSEVIER IRELAND LTD7
- ASCO6
- ELSEVIER SCIENCE INC5
- SAGE5
- SPRINGERNATURE4
Rivista
- DIGESTIVE AND LIVER DISEASE101
- GASTROENTEROLOGY100
- ANNALS OF ONCOLOGY93
- BLOOD89
- JOURNAL OF CLINICAL ONCOLOGY58
- HAEMATOLOGICA56
- NEUROLOGICAL SCIENCES47
- UNITED EUROPEAN GASTROENTEROLOGY ...46
- ANNALS OF THE RHEUMATIC DISEASES36
- REUMATISMO26
Keyword
- Helicobacter pylori10
- sclerosi sistemica6
- Bioengineering5
- Gastroenterology5
- HCV5
- UV5
- GERD4
- Lungs4
- anodal stimulation3
- beat-to-beat variability of cardi...3
Lingua
- eng926
- ita177
- fre1
Accesso al fulltext
- no fulltext1735
- reserved26
- open6